TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03444181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music lessons
Description: Also described as neurocognitive music therapy. Singing lessons will be provided once a week for a period of 12 months by a person with a qualification in music therapy, or by a person with a different relevant qualification (e.g. psychology and music teaching) under the supervision of a music therapist. Additionally, participants will have the opportunity to meet regularly (1-2 times per month) as a choir to sing the song they have learned together in a group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training intervention
Description: Cognitive training that is comparable in scope and extent to the music lessons, but not using music. Group training sessions will be provided once a week for a period of 12 months by a person with a qualification in physiotherapy or occupational therapy. Group activities may include group tours such as mountain hikes and the like (about 2 times per month) and will follow an established program for the elderly.
Study: NCT01494883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: A weekly training of eight sessions lasting two and a half hours.
Study: NCT04084028

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Cooking Classes
Description: 6 cooking classes will be held every week for 6 consecutive weeks. The lessons are patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for those cooking for themselves for the first time. Classes begin with a brief lecture on the day's topic. Students will work in teams of 2 in the foods lab to actively practice skills and cook a meal. Students receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. All students attend a 2 hour kitchen intensive demonstration as an orientation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal Kits
Description: Students receive 6 weeks of home delivered meal kits. Meal kits include ingredients and detailed instructions for 3 meals, which each serve two people. Students may select meals from a list of 18 options that include vegan, vegetarian, and gluten free options.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meal Kits
Description: Students receive 6 weeks of home delivered meal kits. Meal kits include ingredients and detailed instructions for 3 meals, which each serve two people. Students may select meals from a list of 18 options that include vegan, vegetarian, and gluten free options.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recipes
Description: Students are emailed a set of recipes once a week for 6 weeks. Recipes include options for breakfast, lunch, dinner, and snacks. Recipe sets include vegan, vegetarian, and gluten-free options. This intervention was cancelled by COVID-related disruptions and did not take place.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recipes
Description: Students are emailed a set of recipes once a week for 6 weeks. Recipes include options for breakfast, lunch, dinner, and snacks. Recipe sets include vegan, vegetarian, and gluten-free options. This intervention was cancelled by COVID-related disruptions and did not take place.
Study: NCT02234258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral social skills
Study: NCT02750618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Burosumab
Description: solution for subcutaneous injection
Study: NCT03173898

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDL anesthesia versus local infiltration
Description: Every patient received the recommended volumes of 2% lidocaine with 1:100.000 epinephrine for PDL injection on the experimental side, and for local infiltration on the control side. A Visual Analogue Scale (VAS) was used to describe the pain felt during injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDL anesthesia versus local infiltration
Description: Every patient received the recommended volumes of 2% lidocaine with 1:100.000 epinephrine for PDL injection on the experimental side, and for local infiltration on the control side. A Visual Analogue Scale (VAS) was used to describe the pain felt during injection.
Study: NCT04322994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transnasal Humidified Rapid-Insufflation Ventilatory Echange
Description: The use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.
Study: NCT02234258

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Study: NCT00311948

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counseling + interactive website = more abstinence

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral: interactive website
Study: NCT00683722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochymal™
Description: IV infusion of ex- vivo cultured adult human mesenchymal stem cells.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of excipient of Prochymal™.
Study: NCT01415518

Intervention type: DRUG
Group type: OTHER
Intervention: Drug: Budesonide/formoterol (Symbicort Turbuhaler
Description: budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)

Intervention type: DRUG
Group type: OTHER
Intervention: Drug: ipratropium (AtroventTM)
Description: ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)

Intervention type: DRUG
Group type: OTHER
Intervention: Drug: ipratropium (AtroventTM)
Description: ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)

Intervention type: DRUG
Group type: OTHER
Intervention: theophylline SR
Description: theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)

Intervention type: DRUG
Group type: OTHER
Intervention: theophylline SR
Description: theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
Study: NCT04527133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprotinin
Description: Intravenous or inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprotinin
Description: Intravenous or inhalation
Study: NCT02014116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009120 capsule
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009120 capsule
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009120 capsule
Description: Administered orally.
Study: NCT04527133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprotinin
Description: Intravenous or inhalation
Study: NCT02191774

Intervention type: PROCEDURE
Intervention: Medical abortion at home
Description: Medical abortion using Mifepristone at the clinic followed by Cytotec at home

Intervention type: PROCEDURE
Intervention: Medical abortion at home
Description: Medical abortion using Mifepristone at the clinic followed by Cytotec at home
Study: NCT02461433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: Prevena Incision Management system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dressing
Description: This involves standard of care dressing including but not limited to gauze.
Study: NCT02499731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Communities
Description: We will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized controlled intervention trial. We will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 8 intervention and 8 control communities. In addition, we will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong Hearts, Healthy Women
Description: The Strong Hearts, Healthy Women (minimal intervention) will meet once per month for an hour each time for 6 months.~Participants will learn and discuss techniques and strategies to improve personal health.
Study: NCT04169893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (fasting)
Description: Participants will receive placebo once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (fasting)
Description: Participants will receive placebo once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (fasting)
Description: Participants will receive placebo once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (fasting)
Description: Participants will receive placebo once in fasting condition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (feeding)
Description: Participants will receive placebo once after meal condition
Study: NCT02014116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009120 capsule
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009120 capsule
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009120 capsule
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009120 capsule
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009120 capsule
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009120 capsule
Description: Administered orally.
Study: NCT01970033

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Run in period ：oral tablets of Placebo twice daily for 2 weeks~* Phase A : oral tablets of Placebo twice daily for 24 weeks~* Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086 50 mg b.i.d.
Description: * Run-in period: placebo twice daily for 2 weeks~* Phase A:SP2086 50 mg b.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d for 28 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086 100 mg q.d.
Description: * Run-in period:placebo twice daily for 2 weeks~* Phase A: SP2086 100 mg q.d. for 24 weeks~* Phase B: SP2086 100 mg q.d. for 28 weeks
Study: NCT04169893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (feeding)
Description: Participants will receive placebo once after meal condition
Study: NCT05719974

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation protocol
Description: Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises The criterion-based rehabilitation protocol is relatively new. It was developed and recommended in 2016 by the Royal Dutch Society for Physical Therapy (KNGF), aiming to assure a more patient-tailored rehabilitation and to maximize the speed of a patient's progress. It's a three phases protocol with a criterion-based progression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation protocol
Description: Current conventional protocols were based mainly on biological tissue healing time frames. These protocols emphasize pain reduction, full passive knee extension, quadriceps strength training, immediate motion, immediate par¬tial weight bearing (only if there is a correct gait pattern without any complications), and functional exercises The criterion-based rehabilitation protocol is relatively new. It was developed and recommended in 2016 by the Royal Dutch Society for Physical Therapy (KNGF), aiming to assure a more patient-tailored rehabilitation and to maximize the speed of a patient's progress. It's a three phases protocol with a criterion-based progression.
Study: NCT02356380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization Type
Description: Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae.
Study: NCT02522533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: 6 weeks of an exercise program.
Study: NCT04169893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1 mg of TS-142
Description: Participants will receive 1 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg of TS-142
Description: Participants will receive 1 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg of TS-142
Description: Participants will receive 1 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg of TS-142
Description: Participants will receive 1 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3 mg of TS-142
Description: Participants will receive 3 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg of TS-142
Description: Participants will receive 3 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg of TS-142
Description: Participants will receive 3 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg of TS-142
Description: Participants will receive 3 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg of TS-142
Description: Participants will receive 3 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10 mg of TS-142 (fasting)
Description: Participants will receive 10 mg of TS-142 once in fasting condition
Study: NCT03111927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula: enriched level of myelin-relevant nutrients
Description: Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months.
Study: NCT04169893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg of TS-142 (fasting)
Description: Participants will receive 10 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg of TS-142 (fasting)
Description: Participants will receive 10 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg of TS-142 (fasting)
Description: Participants will receive 10 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg of TS-142 (fasting)
Description: Participants will receive 10 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg of TS-142 (fasting)
Description: Participants will receive 10 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10 mg of TS-142 (feeding)
Description: Participants will receive 10 mg of TS-142 once after meal condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg of TS-142 (feeding)
Description: Participants will receive 10 mg of TS-142 once after meal condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg of TS-142 (feeding)
Description: Participants will receive 10 mg of TS-142 once after meal condition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 30 mg of TS-142
Description: Participants will receive 30 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg of TS-142
Description: Participants will receive 30 mg of TS-142 once in fasting condition
Study: NCT03111927

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula: standard level of myelin-relevant nutrients
Description: Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months.
Study: NCT02602301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: different oxytocin diluents and effect on fetal bilirubin\&sodium levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: different oxytocin diluents and effect on fetal bilirubin\&sodium levels.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: different oxytocin diluents and effect on fetal bilirubin\&sodium levels.
Study: NCT01040104

Intervention type: OTHER
Intervention: Skin sample
Description: Taken from regularly discarded tissue during routine operation

Intervention type: OTHER
Intervention: Skin sample
Description: Taken from regularly discarded tissue during routine operation

Intervention type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90

Intervention type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90

Intervention type: OTHER
Intervention: Skin biopsy
Description: Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90

Intervention type: OTHER
Intervention: Skin biopsy
Description: Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90

Intervention type: OTHER
Intervention: Skin biopsy
Description: Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90

Intervention type: OTHER
Intervention: Skin biopsy
Description: Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 0

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 0

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 0

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 0

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 0

Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 0
Study: NCT04169893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg of TS-142
Description: Participants will receive 30 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg of TS-142
Description: Participants will receive 30 mg of TS-142 once in fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg of TS-142
Description: Participants will receive 30 mg of TS-142 once in fasting condition
Study: NCT03442751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Article A
Description: Riboflavin Ophthalmic Solution A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Article B
Description: Riboflavin Ophthalmic Solution B

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo Vehicle of Test Article

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: KXL medical device system
Description: Mock UVA light source

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KXL medical device system
Description: Cross-linking UVA light source
Study: NCT02174263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT00516841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volociximab
Description: 15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops
Study: NCT01860365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary medicine consultation and treatment
Description: Patients receiving chemotherapy will be referred by their oncology provider to complementary medicine (CM) consultation and treatment provided in addition to conventional supportive care.CM consultation will include assessment of patients' concerns and well-being, current CM use (including herbal and nutritional supplements), and construction of CM treatment based on efficacy and safety considerations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients receiving conventional supportive care
Description: Patients receiving chemotherapy will be offered assessment of their concerns and well-being as well as their current complementary medicine (CM) use (including herbal and nutritional supplements). Patients in this arm study will receive conventional supportive care with no added CM consultation or treatment.
Study: NCT01912092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Askina Calgitrol paste
Study: NCT00774163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
Study: NCT02945241

Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Intravenous

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cystatin C dosing algorithm
Description: Expressed in milliliters per minute

Intervention type: OTHER
Group type: OTHER
Intervention: Creatine clearance dosing algorithm
Description: Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
Study: NCT04656756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Care
Description: A clinical and standardized workflow was created for both experimental and control groups. This standardized workflow: consisted of services which included the management of basic medications, routine care regarding the postpartum period, newborn care and health education. After the standardized clinic workflow was formed, a personalized care plan was developed for the experimental group. Each care procedure was shared with the participants in the experimental group. Moreover, all potential alternative care plans were presented to the participants.